FMC63 scFv: the classic antigen recognition domain of CD19-targeted CAR-T therapy

Author: Senior Product Manager of UA Views：7

This article focuses on the molecular characteristics and biological functions of the FMC63 single-chain variable fragment, systematically elaborating on its structural basis as constructed from the heavy chain variable region and light chain variable region of a murine anti-human CD19 IgG2a monoclonal antibody linked by a flexible peptide linker, analyzing its high-specificity binding properties with human CD19 widely expressed on the surface of normal B cells and B-cell malignancies, and discussing its central position as the classic extracellular antigen-recognition domain targeting CD19 in CAR-T cells within approved CAR-T therapies.

Recent Advances
Product Information

Recent Advances

FMC63 scFv: The Classic Antigen-Recognition Domain of CD19-Targeted CAR-T Therapy

Brief Description: This article focuses on the molecular characteristics and biological functions of the FMC63 single-chain variable fragment, systematically describing its structural basis as a construct assembled from the heavy-chain variable region and light-chain variable region of a murine anti-human CD19 IgG2a monoclonal antibody linked by a flexible peptide linker. It analyzes its high-specificity binding properties to human CD19, which is widely expressed on the surface of normal B cells and B-cell malignancies, and discusses its central position as the classic extracellular antigen-recognition domain of CD19-targeted CAR-T cells in approved CAR-T therapies.

I. Molecular Origin and Structural Composition of FMC63 scFv

FMC63 single-chain variable fragment is a recombinant single-chain variable fragment assembled from the heavy-chain variable region and light-chain variable region of the murine anti-human CD19 IgG2a monoclonal antibody FMC63 linked by a flexible peptide linker. Its molecular design follows the classic construction logic of single-chain antibodies: the antibody heavy-chain variable region and light-chain variable region are connected via an artificially designed linker peptide gene into a single open reading frame, and after expression, the smallest antibody functional unit capable of retaining antigen-binding activity is formed. The flexible peptide linker is usually composed of glycine and serine residues, giving the two variable regions sufficient spatial freedom so that they can still pair correctly after folding to form a complete monovalent antigen-binding site. This structural design, while retaining the antigen-recognition specificity of the parent antibody, greatly reduces the molecular size and facilitates subsequent genetic engineering modifications.

II. High-Specificity Binding Properties of FMC63 scFv to CD19

This fragment maintains high-specificity binding affinity to human CD19, which is widely expressed on the surface of normal B cells and B-cell malignancies. CD19 is a transmembrane glycoprotein specifically expressed in the B-lymphocyte lineage, continuously expressed from the pro-B cell stage through the pre-B cell, immature B cell, and mature B cell stages, maintained at high expression in the vast majority of B-cell malignancies, and lost after terminal differentiation of B cells into plasma cells. This broad and stable expression pattern on the surface of both normal and malignant B cells makes CD19 an ideal target for targeted therapy of B-cell malignancies, and also makes FMC63 scFv, which recognizes CD19, one of the most classic and reliable antigen-recognition modules for constructing CAR-T cells. The high-specificity binding of FMC63 scFv to CD19 is the molecular prerequisite for CAR-T cells to precisely recognize and kill B-lineage tumor cells.

III. The Central Position of FMC63 scFv in Approved CAR-T Therapies

FMC63 scFv is the classic extracellular antigen-recognition domain of CD19-targeted CAR-T cells, and four CAR-T therapies approved by the U.S. Food and Drug Administration, including Kymriah and Yescarta, all use this sequence. This fact itself constitutes the strongest proof of the clinical value of FMC63 scFv——the independent selection of the same antigen-recognition domain by multiple products during their separate development reflects the comprehensive advantages of this sequence in terms of affinity, specificity, expression stability, and safety after long-term clinical validation. As the extracellular portion of the CAR molecule, FMC63 scFv determines the antigen specificity with which CAR-T cells recognize target cells; upon binding to CD19, it induces CAR molecule aggregation and thereby activates the killing function of T cells through intracellular signaling domains. Therefore, FMC63 scFv is not only the “eyes” of CAR-T therapy but also the initiating link of the entire recognition-activation signaling chain.

IV. Application Value of FMC63 scFv in Preclinical Research

This recombinant protein can be used in preclinical immunotherapy vector construction, CD19 binding validation, CAR detection, and affinity characterization experiments. In vector construction, the FMC63 scFv coding sequence is the core element for constructing CD19-targeted CAR expression vectors. In CD19 binding validation, the recombinant FMC63 scFv protein can be used to confirm its binding activity to CD19-positive cells or recombinant CD19 protein. In CAR detection, the FMC63 scFv protein can serve as a detection reagent for flow cytometry evaluation of the expression level of CAR molecules on the surface of CAR-T cells. In affinity characterization, this protein can be used in surface plasmon resonance or bio-layer interferometry to determine the binding kinetic parameters of its interaction with CD19. These application scenarios cover the entire CAR-T research and development process from vector design to product quality control, making the FMC63 scFv recombinant protein an indispensable tool molecule in preclinical research.

V. Conclusion

In basic research related to FMC63 scFv and CAR-T drug development, high-quality recombinant FMC63 scFv protein is a core tool for elucidating its binding mechanism with CD19 and evaluating CAR-T product quality. The His tag facilitates purification by immobilized metal affinity chromatography and enables detection and capture via anti-His tag antibodies. To meet the needs of FMC63 scFv functional research and CAR-T development, Univ provides FMC63 scFv His Tag Protein. This product is suitable for applications such as binding activity analysis of FMC63 scFv to CD19, flow cytometric detection of CAR molecules on the surface of CAR-T cells, construction and validation of CD19-targeted CAR expression vectors, and affinity characterization of the binding kinetic parameters of FMC63 scFv to CD19.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Next